XTRA:VSC

Stock Analysis Report

Executive Summary

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs.

Snowflake

Fundamentals

Excellent balance sheet with weak fundamentals.

Share Price & News

How has 4SC's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

VSC

-0.4%

DE Biotechs

2.4%

DE Market


1 Year Return

-43.3%

VSC

1.8%

DE Biotechs

4.9%

DE Market

Return vs Industry: VSC underperformed the German Biotechs industry which returned 1.8% over the past year.

Return vs Market: VSC underperformed the German Market which returned 4.9% over the past year.


Shareholder returns

VSCIndustryMarket
7 Day0%-0.4%2.4%
30 Day1.5%-5.4%2.3%
90 Day-5.5%-6.7%2.7%
1 Year-40.9%-43.3%2.0%1.8%8.2%4.9%
3 Year-13.3%-16.7%67.9%66.1%18.3%8.0%
5 Year-57.8%-60.9%12.0%9.5%44.2%24.6%

Price Volatility Vs. Market

How volatile is 4SC's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is 4SC undervalued compared to its fair value and its price relative to the market?

3.19x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate VSC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate VSC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: VSC is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: VSC is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VSC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VSC is overvalued based on its PB Ratio (3.2x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is 4SC forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-7.9%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if VSC's forecast earnings growth is above the savings rate (0.2%).

Earnings vs Market: Insufficient data to determine if VSC's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: VSC's revenue is expected to decline over the next 3 years (-7.9% per year).

High Growth Revenue: VSC's revenue is forecast to decline over the next 3 years (-7.9% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VSC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has 4SC performed over the past 5 years?

-13.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: VSC is unprofitable, and losses have increased over the past 5 years at a rate of -13.7% per year.

Accelerating Growth: Unable to compare VSC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4%).


Return on Equity

High ROE: VSC has a negative Return on Equity (-72.15%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: VSC is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: VSC is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is 4SC's financial position?


Financial Position Analysis

Short Term Liabilities: VSC's short term assets (€21.2M) exceeds its short term liabilities (€3.8M)

Long Term Liabilities: VSC's short term assets (21.2M) exceeds its long term liabilities (1.7M)


Debt to Equity History and Analysis

Debt Level: VSC is debt free.

Reducing Debt: VSC has no debt compared to 5 years ago when its debt to equity ratio was 29.7%.


Balance Sheet

Inventory Level: VSC has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if VSC's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VSC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: VSC has less than a year of cash runway if free cash flow continues to reduce at historical rates of -13.9% each year


Next Steps

Dividend

What is 4SC's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate VSC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate VSC's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if VSC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VSC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VSC's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

What is the CEO of 4SC's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Jason Loveridge 0

3.1yrs

Tenure

€669,000

Compensation

Dr. Jason Loveridge, B.Sc, PhD, FRSM, has been Corporate Advisor of Resonance Health Limited since June 30, 2017. Dr. Loveridge has been Chairman of Management Board and Chief Executive Officer of 4SC AG s ...


CEO Compensation Analysis

Compensation vs. Market: Jason's total compensation ($USD745.32K) is about average for companies of similar size in the German market ($USD215.15K).

Compensation vs Earnings: Jason's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.1yrs

Average Tenure

Experienced Management: VSC's management team is considered experienced (3.1 years average tenure).


Board Age and Tenure

6.1yrs

Average Tenure

57.5yo

Average Age

Experienced Board: VSC's board of directors are considered experienced (6.1 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Jason Loveridge

    Chairman of Management Board

    • Tenure: 3.1yrs
    • Compensation: €669.00k
  • Susanne Danhauser-Riedl

    Chief Medical Officer

    • Tenure: 4.5yrs
  • Frank Hermann

    Chief Development Officer

    • Tenure: 2.8yrs
  • Anna Niedl

    Corporate Communications & Investor Relations Officer

    • Tenure: 0yrs

Board Members

  • Manfred Rüdiger (55yo)

    Member of Supervisory Board

    • Tenure: 14.2yrs
  • Clemens Doppler (60yo)

    Chairman of Supervisory Board

    • Tenure: 5.1yrs
  • Helmut Jeggle (49yo)

    Member of Supervisory Board

    • Tenure: 11.3yrs
  • Irina Antonijevic (54yo)

    Member of Supervisory Board

    • Tenure: 7.2yrs
  • Helga Rübsamen-Schaeff (70yo)

    Member of Supervisory Board

    • Tenure: 4.8yrs
  • Joerg von Petrikowsky (61yo)

    Deputy Chairman of Supervisory Board

    • Tenure: 3.3yrs
  • Charles Epstein

    Member International Scientific Expert Panel

    • Tenure: 0yrs
  • Wolff Schmiegel

    Member International Scientific Expert Panel

    • Tenure: 0yrs

Company Information

4SC AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: 4SC AG
  • Ticker: VSC
  • Exchange: XTRA
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €73.123m
  • Shares outstanding: 35.33m
  • Website: https://www.4sc.de

Number of Employees


Location

  • 4SC AG
  • Fraunhoferstrasse 22
  • Planegg
  • Bavaria
  • 82152
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
VSCDB (Deutsche Boerse AG)YesCommon Bearer SharesDEEURDec 2005
VSCXTRA (XETRA Trading Platform)YesCommon Bearer SharesDEEURDec 2005
0R6ULSE (London Stock Exchange)YesCommon Bearer SharesGBEURDec 2005

Biography

4SC AG, a clinical-stage biopharmaceutical company, engages in developing small-molecule drugs that target key indications in cancer with high unmet medical needs. The company’s drugs are intended to provi ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/21 20:55
End of Day Share Price2019/10/21 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.